Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.55 |
| ▸ | XIAP | P98170 | 1/20 | 0.55 |
| ▸ | TYR | P14679 | 5/20 | 0.47 |
| ▸ | TPH1 | P17752 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19704241 | 1.00 | SLC7A5 (0.61) | SLC7A5HSD17B10PTGS1ALOX15HIF1A | |
| SCHEMBL18375252 | 0.86 | SLC7A5 (0.43) | SLC7A5HSD17B10PTGS1ALOX15HIF1A | |
| SCHEMBL25578551 | 0.86 | SLC7A5 (0.43) | SLC7A5HSD17B10PTGS1ALOX15HIF1A | |
| SCHEMBL20369611 | 0.86 | SLC7A5 (0.43) | SLC7A5HSD17B10PTGS1ALOX15HIF1A | |
| SCHEMBL26008176 | 0.83 | CPB2 (0.63) | SLC7A5HSD17B10PTGS1ALOX15HIF1A | |
| SCHEMBL4629770 | 0.83 | CPB2 (0.63) | SLC7A5HSD17B10PTGS1ALOX15HIF1A | |
| SCHEMBL15314368 | 0.83 | CPB2 (0.63) | SLC7A5HSD17B10PTGS1ALOX15HIF1A | |
| SCHEMBL25355779 | 0.81 | P4HTM (0.57) | SLC7A5HSD17B10PTGS1ALOX15HIF1A | |
| SCHEMBL2073432 | 0.81 | HSD17B10 (0.57) | SLC7A5HSD17B10PTGS1ALOX15HIF1A | |
| SCHEMBL5291267 | 0.81 | HSD17B10 (0.57) | SLC7A5HSD17B10PTGS1ALOX15HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9844509-B2 | High throughput fabrication of nanoparticles | PFIZER INC. (US) | 2017-12-19 | — | — | US | claimed |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | RAYZEBIO, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025137443-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025137441-A1 | RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20230174460-A1 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-08 | — | — | US | disclosed |
| WO-2021216781-A1 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2020194563-A1 | AGENT FOR PREVENTING OR IMPROVING SYMPTOMS OR DISEASE CAUSED BY PHENOLS | 国立大学法人東北大学 | 2020-10-01 | — | — | WO | disclosed |
| EP-2793027-B1 | Unnatural reactive amino acid genetic code additions | SCRIPPS RESEARCH INST (US) | 2019-11-13 | — | — | EP | disclosed |
| US-9797908-B2 | Unnatural reactive amino acid genetic code additions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-10-24 | — | — | US | disclosed |
| US-9580721-B2 | Expanding the eukaryotic genetic code | The Scripps Reserach Institute (US) | 2017-02-28 | — | — | US | disclosed |
| US-20080176277-A1 | Expanding the eukaryotic genetic code | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-07-24 | — | — | US | disclosed |
| US-20070166791-A1 | Expanding the eukaryotic genetic code | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070154952-A1 | Expanding the eukaryotic genetic code | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-07-05 | — | — | US | disclosed |
| US-20060246509-A1 | protein containing an amino acid that carries an azido or alkynyl group for conjugation to a second molecule such as polymer, label or drug by a [3+2] cycloaddition; translation biochemistry in eukaryotic cells; gene expression inhibitors | THE SCRIPPS RESEARCH INSTITUTE | 2006-11-02 | — | — | US | disclosed |
| EP-1636340-A2 | UNNATURAL REACTIVE AMINO ACID GENETIC CODE ADDITIONS | The Scripps Research Institute (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1613735-A2 | EXPANDING THE EUKARYOTIC GENETIC CODE | The Scripps Research Institute (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050009049-A1 | Expanding the eukaryotic genetic code | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-01-13 | — | — | US | disclosed |
| WO-2005003294-A2 | UNNATURAL REACTIVE AMINO ACID GENETIC CODE ADDITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20040265952-A1 | protein containing a modified amino acid that carries an azido or alkynyl group for conjugation to a second molecule such as polymer, label or drug that carries an alkynyl or azido group; translation biochemistry in eukaryotic cells; gene expression inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-12-30 | — | — | US | disclosed |
| WO-2004094593-A2 | EXPANDING THE EUKARYOTIC GENETIC CODE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070154952-A1 | Expanding the eukaryotic genetic code | NSUN3, AARS1, TRMT1 | SLC7A5 263/4885HSD17B10 1956/4885PTGS1 3470/4885 |
| US-20050009049-A1 | Expanding the eukaryotic genetic code | NSUN3, AARS1, TRMT1 | SLC7A5 263/4885HSD17B10 1956/4885PTGS1 3470/4885 |
| US-20060246509-A1 | protein containing an amino acid that carries an azido or alkynyl group for conjugation to a second molecule such as polymer, label or drug by a [3+2] cycloaddition; translation biochemistry in eukaryotic cells; gene expression inhibitors | AARS1, ASNS, KARS1 | SLC7A5 431/4885HSD17B10 2154/4885PTGS1 4151/4885 |
| US-20230174460-A1 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | PARK7, SNCA, RHOT2 | SLC7A5 772/4885HSD17B10 2331/4885PTGS1 2147/4885 |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | SSTR2, SSTR4, SSTR5 | SLC7A5 286/4885HSD17B10 4794/4885PTGS1 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.